Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer-Reference-Cited by-同舟云学术

Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer

Published:2024-01-11 Issue:6 Volume:51 Page:1763-1772
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Kim Jisu,Lee Seunghwan,Kim Dongwoo,Kim Hyun Jeong,Oh Kyeong Taek,Kim Sun Jung,Choi Young Deuk,Giesel Frederik L.,Kopka Klaus,Hoepping Alexander,Lee Misu,Yun Mijin

Funder

National Research Foundation of Korea

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06585-7.pdf

Reference35 articles.

1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10:63–89. https://doi.org/10.14740/wjon1191

2. Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting Prostate cancer. Cochrane Database Syst Rev. 2019;4:CD012663. https://doi.org/10.1002/14651858.CD012663.pub2

3. Woodrum DA, Gorny KR, Greenwood B, Mynderse LA. MRI-Guided prostate biopsy of native and recurrent Prostate Cancer. Semin Interv Radiol. 2016;33:196–205. https://doi.org/10.1055/s-0036-1586151

4. Troyer JK, Beckett ML, Wright GL. Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552–8. https://doi.org/10.1002/ijc.2910620511

5. Oh SW, Suh M, Cheon GJ. Current status of PSMA-Targeted Radioligand Therapy in the era of Radiopharmaceutical Therapy acquiring marketing authorization. Nucl Med Mol Imaging. 2022;56:263–81.